Despite efforts for improvement, the "State of the Air" report reveals concerns.

Published Date: 23 Apr 2023

Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.

Read Full News

Latest News

STABLE Trial: Breath-Hold Does Not Improve Robotic Bronchoscopy Yield Roshen Mathew, MD, DAABIP

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes Michael Wechsler, MD, MSc

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

HCPLive Five at CHEST 2026

HCPLive Five at CHEST 2026

Experts Discuss PAH Treatment Selection and Access

Experts Discuss PAH Treatment Selection and Access

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA Frank C. Sciurba, MD

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Todays Updates

AI Could Help Find Undiagnosed COPD on Lung Cancer Screening CT Jean Bourbeau, MD

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Inhaled Treprostinil Reduces Recurrent IPF Events, With Steven Nathan, MD Steven D. Nathan, MD, FCCP

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Understanding Advances Shaping Precision Medicine for Generalized Myasthenia Gravis Marco Meglio

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

NeurologyLive® Friday 5 — October 30, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.

Distinguishing Lambert-Eaton Myasthenic Syndrome From Myasthenia Gravis: Ocular and Systemic Clues Isabella Ciccone, MPH

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Balcinrenone Plus Dapagliflozin Lowers BP, With Adriana Marton, MD

Balcinrenone Plus Dapagliflozin Lowers BP, With Adriana Marton, MD

Todays Updates

AI Could Help Find Undiagnosed COPD on Lung Cancer Screening CT Jean Bourbeau, MD

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Inhaled Treprostinil Reduces Recurrent IPF Events, With Steven Nathan, MD Steven D. Nathan, MD, FCCP

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Understanding Advances Shaping Precision Medicine for Generalized Myasthenia Gravis Marco Meglio

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

NeurologyLive® Friday 5 — October 30, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.

Distinguishing Lambert-Eaton Myasthenic Syndrome From Myasthenia Gravis: Ocular and Systemic Clues Isabella Ciccone, MPH

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Balcinrenone Plus Dapagliflozin Lowers BP, With Adriana Marton, MD

Balcinrenone Plus Dapagliflozin Lowers BP, With Adriana Marton, MD

Latest News

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

HCPLive Five at CHEST 2026

Experts Discuss PAH Treatment Selection and Access

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

News All Time

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know

CHEST 2026: Day 3 Recap — 6 Headlines to Know

Why Oxygen Stigma Persists, With Mike Hess, MPH Mike Hess, MPH

On World Oxygen Day, the COPD Foundation's Mike Hess outlines the stigma, training gaps, and Medicare barriers affecting patients on supplemental oxygen.

When to Switch Biologics in Severe Asthma, With Florence Schleich, MD, PhD Florence Schleich, MD, PhD

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Lower Baseline FVC Linked to Better Sarcoidosis Treatment Response Vivienne Kahlmann

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.
HTTP error: 503

Recommended News For You

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

Gene Therapy for Rare Brain Disease Effective, but Comes With Blood Cancer Risk

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

US Mental Health Treatment Rates Rise But Gaps Persist

Encounters matter in cancer care: Health care professionals can play a key role in restoring patients' sense of control

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

Recommended Articles For You

The Algorithmic Revolution: How AI is Reshaping Precision Oncology from Bench to Bedside 

Emerging Therapies Using Ex Vivo Hematopoietic Tissue Engineering for Marrow Recovery 

Multi-Omic Rejuvenation of Aged Tissues With Transient Reprogramming and Its Therapeutic Potential 

Case Study: Artificial Intelligence in Early Cancer Detection 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot